Apathy and anxiety are early markers of Alzheimer’s disease.

2020

https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0197458019303719?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0197458019303719%3Fshowall%3Dtrue&referrer=https:%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F%3Fterm%3D10.1016%252Fj.neurobiolaging.2019.10.008

Johansson M, Stomrud E, Lindberg O, Westman E, Johansson PM, van Westen D, Mattsson N, Hansson O.

Neurobiol Aging. 2020 Jan;85:74-82.

2024 The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation
2024 Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
2024 MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population
2024 Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
2024 Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model
2024 A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease
2024 Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
2024 Divergent functional connectivity changes associated with white matter hyperintensities
2024 Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
2024 Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
2024 A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
2024 A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests
2024 Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
2024 Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease
2024 Revised criteria for the diagnosis and staging of Alzheimer’s disease